Core Insights - Danone Nutricia Pharmaceutical (Wuxi) Co., Ltd. has officially completed the topping-out of its factory expansion project, which aims to enhance the production capacity of enteral nutrition suspensions through the establishment of multiple fully automated sterilization production lines [1] Group 1: Company Development - The expansion project signifies that Danone Nutricia's medical nutrition business in China is entering a phase of accelerated growth [1] - Danone has outlined a mid-term development strategy for 2025-2028 that emphasizes the acceleration of its medical nutrition business [1] Group 2: Product and Market Focus - Danone Nutricia Pharmaceutical (Wuxi) Co., Ltd. was established in 2000 and has developed a comprehensive product system covering enteral nutrition products and supporting medical devices in the Chinese market [1] - The Wuxi factory produces enteral nutrition formulations such as Nengquan and Baipuli, as well as the Fulekai enteral nutrition infusion system, which serve various clinical fields including oncology, stroke, allergies, gastrointestinal diseases, and elderly nutrition [1] - In 2018, the Wuxi factory initiated a special medical nutrition food project and launched the Nengquanli Yijia special medical purpose full-nutrition formula food in 2023, targeting individuals over 10 years old with eating restrictions, digestive absorption disorders, or metabolic disorders [1]